BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30070694)

  • 1. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
    Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
    Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 3. TERT promoter mutations in melanoma survival.
    Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
    Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
    Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
    Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
    Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
    Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
    Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
    Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
    Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
    Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
    Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
    Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
    Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
    Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
    Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
    PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
    Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
    Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
    Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H
    Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
    Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
    Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.